This result indicated that collagen/integrin β1/Src signal transduction was a key regulatory pathway that mediated the resistance of HER2+ breast cancer to anti-HER and anti-PI3K inhibitor combination therapy. This evidence concerns the gene ERBB2 and breast cancer.